Danish biotech firm Genmab and US biotech firm Seagen have applied for an accelerated approval of the drug candidate tisotumab vedotin at the US Food and Drug Administration, according to a Genmab press release on Wednesday.
Tisotumab vedotin has been proclaimed as one of Genmab's future pipeline hopes. The firm shares ownership of tisotumab vedotin with the US biotech firm Seagen, which used to go by the name Seattle Genetics.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.